Navigation Links
Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
Date:9/24/2007

- Publication in Leading Peer-Reviewed Journal Represents Further Scientific Validation of the Potential Utility of Modigene's CTP Technology

-

VIENNA, Va., Sept. 24 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG) today reported that researchers will publish a study in the October edition of the journal Endocrinology showing that erythropoietin (EPO) linked to Modigene's carboxyl terminal peptide (CTP) technology significantly increased the half-life of standard EPO in animal models.(1) The study, which assessed an early version of EPO-CTP, showed that a single weekly injection was as effective in raising hematocrit levels as the same total dose of standard EPO administered in three injections over the course of a week.

The current version of EPO-CTP in preclinical development at Modigene has further extended the duration of the drug, demonstrating in animal models an approximately 33% longer half-life and greater biological activity than Aranesp(R), Amgen's long-acting EPO.

"The publication of this study in the respected journal Endocrinology further validates the growing body of clinical and preclinical data supporting the ability of CTP technology to significantly extend the half-life and duration of action of therapeutic proteins," said Dr. Fuad Fares, lead author of the study and Chief Scientific Officer of Modigene. "Long-acting therapeutic protein drugs are increasingly important treatments for a variety of diseases, and we believe the demonstrated ability of our CTP technology to reduce the frequency of required injections could provide important benefits to the many patients who depend on these drugs. We look forward to advancing our first CTP-enhanced drug candidates into clinical trials next year."

Modigene is conducting late-stage preclinical studies of CTP-enhanced protein drugs including human growth hormone, interferon beta and EPO. All three have demonstrated s
'/>"/>

SOURCE Modigene Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
...  Aria Diagnostics, a molecular diagnostics company, today announced ... examines the accuracy of its non-invasive prenatal test ... Down syndrome) and Trisomy 18 (associated with Edwards ... with a proprietary algorithm to assess individualized risk ...
... Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that ... of Gastrodia valued at 67.5 Million RMB or approximately ... Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and ... of Gastrodia from January 1, 2012 to December 31, 2012. ...
Cached Medicine Technology:Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on Thursday, ... of the Supreme Court decision Roe v. Wade, which legalized abortion ... Roe vs. Wade decision and the fight to protect a women’s ... of West Hollywood Councilmember Abbe Land. “We need to continue to ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... , CHARLESTON, W.Va., Dec. 4 UniCare ... and West Virginia Radio Corporation will be holding the ... Mission. Several local celebrities, including 2006 World,s Strongest Man ... State Natalie Tenant, and Governor and Mrs. Manchin will ...
... ... an information technology (IT) and web products and services provider for ... -hospital web sites earned ten awards in the Strategic Communications ... Solutions Executive Director of web products and services, Chris Catallo, at ...
... been made over the last 15 years in the healthcare ... Yet this progress in epilepsy management has not reached ... many of the nearly three million people in the United ... Schachter, M.D., president of the American Epilepsy Society (AES), there ...
... first indication they understand what 2-D images represent, researchers ... can recognize photographs of other monkeys they know, proving ... figure out if they,ve seen them before, researchers report. ... decipher the two-dimensional nature of a photograph, the scientists ...
... LOS ANGELES, Dec. 4 Yogen Fruz , the world,s ... themed "NUmixes" -- Yog-Nog and Mint Chocolate Chip ... at Yogen Fruz stores across North America. Yogen Fruz,s low-calorie Yog-Nog ... alternative to indulge in this holiday season. , "We ...
... ... of novel and effective computational methods for drug discovery, has joined ... developing rare chemical trading platform and builds database of commercially available ... chemists at InhibOx where they incorporate it into the virtual screening ...
Cached Medicine News:Health News:UniCare, Walmart Organize Circle of Hope To Help Mountain Mission Meet Increased Demand for Assistance 2Health News:CareTech Solutions Web Clients Earn Top Recognition in the Tenth Annual eHealthcare Leadership Awards Competition 2Health News:CareTech Solutions Web Clients Earn Top Recognition in the Tenth Annual eHealthcare Leadership Awards Competition 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 4Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3
... any arm -- simply bend the aluminum forearm ... The cuffs are connected by an aluminum bar ... elbow angle. The central part of the joiner ... elbow joint.,Special attention is paid to the patient ...
... lightweight ankle splint may be used for ... ankle. It is effective in stabilizing ... or after cast removal. The rigid ... excellent side-to-side support. The stays also ...
... is designed to assist ambulation for those ... resulting in drop-foot. The anatomically correct shape ... is fabricated from specially formed orthopedic grade ... and reliability. For a more comfortable individual ...
... The VacoSplint has a rigid shell with ... an immobilized foot/ankle. The VacoSplint is a non-weight ... weight bear he/she should transfer to the STORM ... remove the nylon liner from the STORM and ...
Medicine Products: